1 / 14

Resource Allocation in Translational Neuroscience: An Industry Perspective in 2009

Resource Allocation in Translational Neuroscience: An Industry Perspective in 2009. Janet Vergis President Janssen, McNeil Pediatrics, and Ortho-McNeil Neurologics. What’s on Our Minds. Declining pipeline productivity. Key Considerations. P olicy P ayers, providers, patients

ince
Download Presentation

Resource Allocation in Translational Neuroscience: An Industry Perspective in 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Resource Allocation in Translational Neuroscience: An Industry Perspective in 2009 Janet Vergis President Janssen, McNeil Pediatrics, and Ortho-McNeil Neurologics

  2. What’s on Our Minds

  3. Declining pipeline productivity

  4. Key Considerations • Policy • Payers, providers, patients • Patient Segmentation • Platform Advances

  5. Policy • Healthcare Reform • Changes in Medicare/Medicaid • Value-based purchasing • Medical home model • Increased transparency • Comparative Effectiveness • FDA reform • Patent legislation

  6. Providers, Patients & Payors

  7. The Many Stakeholders of US Healthcare Policy Makers Influencers • Health policy (CMS, APHA, AMA) • Quality initiatives (NCQA, NCF) • Advocacy Health Care Funders • Employers • Government (CMS, Medicaid) • Consumers Intermediaries • MCO, PBMs • Medicare Providers (PDPs) • Retail Chains/Wholesalers Providers • Hospitals, Clinics • Physicians & Health Professionals • Pharmacies Patients & Caregivers • Employees • Elderly/Disabled • In-home caregivers

  8. Platform Advances • Biomarkers and tools – RNAi, Neuroimaging, genetics, epigenetics, genomics, proteomics, metabolomics • PGx – Personalized Medicine • Stem Cell research – Neurogenesis • Bioinformatics – Computational modeling, In silico clinical trials • Nanotechnologies – Neuroprotection, Transport across blood brain barrier • Health Information Technology • Drug-Device combos

  9. Patient Segmentation DSM V

  10. Key Investment Questions • Where are the greatest unmet needs? • How can we bring true value to the market? • What forces (social, scientific, economic, political) will be shaping the health care market when the medicine is approved? • What are our capabilities? Where should we outsource? • What can we discover/develop? What must we in-license? • How are we going to use recent advances in technology to develop better drugs more efficiently? • How much IP can we share… or must we share? How can we better coordinate efforts in the pre-competitive space? • How do we balance long term (> 10 years) and short-term (5-10 years) investments? • What is the ratio of investment toward advancing the science, public health, and our products?

  11. New mindsetin R&D Closed Model Innovation and advancement prioritized over entity  Co-creation and sharing of intellectual property (risk & reward) Wider range of expertise – merging of private and public and external industry best practices Open Model • Entity prioritized over ideas, technologies, and economies • Simplistic investment model (own risk & reward) • Siloed R&D and idea generation Focus on consumer needs

  12. Expanding Approaches to Innovation Research Pool

  13. “The significant problems we face cannot be solved at the same level of thinking we were at when we created them.” Albert Einstein

  14. Resource Allocation in Translational Neuroscience: An Industry Perspective in 2009 Janet Vergis President Janssen, McNeil Pediatrics, and Ortho-McNeil Neurologics

More Related